Advertisement

Topics

Sales decline slows in third quarter, AstraZeneca says brighter future ahead

10:23 EST 9 Nov 2017 | thePharmaLetter

The UK’s AstraZeneca has released third quarter results showing revenue of $6.2 billion, a 9% rise…

Original Article: Sales decline slows in third quarter, AstraZeneca says brighter future ahead

NEXT ARTICLE

More From BioPortfolio on "Sales decline slows in third quarter, AstraZeneca says brighter future ahead"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...